ImmuSmol

Immusmol: the Small Molecule Antibody Company

Founded in 2012 by immunologist Dr Alban Bessede, ImmuSmol aims at becoming a natural choice for small molecule antibodies. Supported by a French group with annual revenues exceeding 1,3 billion euros, the company was established in 2013 in Pessac, France, just a few miles from the famous "Pessac-Léognan" Bordeaux wine estates.

Our focus: antibodies targeting small molecules

ImmuSmol stands for “immunoglobulins [antibodies] against small molecules”. While traditional antibodies only recognize large molecules such as proteins, ImmuSmol designs and develops antibodies capable of targeting low molecular weight entities (<900 Da).

Amino acids, lipids, saccharids, toxins, drugs, … virtually any small molecule can thus be addressed with high affinity and specificity. Fully compatible with existing antibody-based technologies, small molecule antibodies are opening a whole new set of possibilities in research, diagnostics and therapy.

Three core applications

  • Research antibodies - ImmuSmol sells validated primary antibodies, for small molecule detection and visualization in cells and tissues.
  • Custom services - ImmuSmol offers to raise antibodies targeting small molecules for research, diagnostic and therapeutic applications.
  • Diagnostics & Therapy - Three personalized medicine programs based on proprietary small molecule antibodies are currently under development.
We can't find products matching the selection.

Have questions?

An ARP Customer Service Representative is happy to help!